var data={"title":"Non-falciparum malaria: Plasmodium knowlesi","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Non-falciparum malaria: Plasmodium knowlesi</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/contributors\" class=\"contributor contributor_credentials\">Nicholas M Anstey, MBBS, FRACP, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/contributors\" class=\"contributor contributor_credentials\">Bridget Emily Barber, MBBS, MPH, FRACP, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/contributors\" class=\"contributor contributor_credentials\">Timothy William, MBBS, FRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/contributors\" class=\"contributor contributor_credentials\">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 26, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1863622304\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Plasmodium knowlesi</em> is a simian malaria parasite; the natural hosts are macaques [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/1\" class=\"abstract_t\">1</a>]. Human cases of knowlesi malaria have been reported throughout Southeast Asia; the greatest number of cases have been reported from Malaysia, particularly the eastern Malaysian states of Sabah and Sarawak [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Human <em>P. knowlesi </em>infection is generally acquired in forest or forest-fringe areas; those at risk include farmers, plantation workers, and individuals undertaking other activities in forested areas [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/3\" class=\"abstract_t\">3</a>]. Infection occurs more commonly in adults than in children [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/3-5\" class=\"abstract_t\">3-5</a>]; the risk of severe disease increases with age [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Issues related to non-falciparum malaria due to <em>Plasmodium knowlesi</em> are reviewed here [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Issues related to non-falciparum malaria due to <em>Plasmodium vivax, Plasmodium ovale,</em> and <em>Plasmodium malariae</em> are discussed separately. (See <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H463928145\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H3451033369\"><span class=\"h2\">Geographic distribution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The first case of naturally acquired human infection with <em>P. knowlesi</em> was reported in 1965 in a United States national working in Malaysia [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/9\" class=\"abstract_t\">9</a>]. Subsequently, a large focus of naturally acquired <em>P. knowlesi</em> infections in humans in the eastern Malaysian state of Sarawak was described in 2004 [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/10\" class=\"abstract_t\">10</a>]. Following this report, <em>P. knowlesi</em> was found to be widely distributed throughout Sarawak and the other eastern Malaysian state of Sabah as well as in Peninsular Malaysia [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/11\" class=\"abstract_t\">11</a>]. The infections occurred in patients who had been diagnosed by microscopy as infected with <em>P. malariae</em>, which is morphologically similar. A map of the predicted risk of <em>P. knowlesi</em> infection throughout Southeast Asia is provided in the figure (<a href=\"image.htm?imageKey=ID%2F115652\" class=\"graphic graphic_figure graphicRef115652 \">figure 1</a>).</p><p>The geographic distribution of <em>P. knowlesi</em> reflects that of the simian hosts, the long-tailed macaque (<em>Macaca fascicularis</em>) and pig-tailed macaque (<em>Macaca nemestrina</em>), and the mosquito vector (<em>Anopheles leucosphyrus</em>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/12\" class=\"abstract_t\">12</a>]. These macaque species have a geographic distribution that extends from India, Bhutan, and Bangladesh eastwards through to the Philippines and southwards to Indonesia. The <em>An. leucosphyrus</em> group mosquitoes have a similar distribution across this region.</p><p>Human cases of <em>P. knowlesi</em> have been reported throughout this region, including in Myanmar, Thailand, Cambodia, southern China, Vietnam, Philippines, Singapore, Malaysia, the Andaman Islands in India, and Kalimantan and Sumatra, Indonesia [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/13-16\" class=\"abstract_t\">13-16</a>]. An increasing number of cases have also been reported in travelers returning from these regions [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/17\" class=\"abstract_t\">17</a>].</p><p>The greatest number of cases have been reported in the eastern Malaysian states of Sabah and Sarawak. In these states, <em>P. knowlesi</em> has become the predominant cause of human malaria; cases of <em>P. falciparum</em> and <em>P. vivax</em> have reduced substantially [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/4,5,18\" class=\"abstract_t\">4,5,18</a>]. In 2014, there were 1325 cases of <em>P. knowlesi</em> reported in Sabah and 1098 cases reported in Sarawak; these accounted for 76 and 84 percent of reported cases, respectively [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18,19\" class=\"abstract_t\">18,19</a>].</p><p class=\"headingAnchor\" id=\"H3881578288\"><span class=\"h2\">Transmission and risk factors for infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Humans are incidentally infected with <em>P. knowlesi</em> when bitten by a mosquito vector that has fed from a macaque reservoir host. Human-mosquito-human transmission has been demonstrated in a laboratory setting but has not yet been proven to occur in the natural environment [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/20\" class=\"abstract_t\">20</a>]. Human cases of <em>P. knowlesi</em> have been reported to occur in clusters, with individuals of all ages affected; therefore, while transmission is predominantly zoonotic, it appears possible that human-mosquito-human transmission may occur (at least to some degree) in endemic areas [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Risk factors for acquiring <em>P. knowlesi</em> infection include [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/3\" class=\"abstract_t\">3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age &ge;15 years</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Male gender</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Work involving farming, plantations, or clearing vegetation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sleeping outside</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Proximity to monkeys in the preceding four weeks</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of open eaves or gaps in walls</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of long grass around dwelling</p><p/><p>Protective factors against <em>P. knowlesi </em>infection in one study included glucose-6-phosphate dehydrogenase (G6PD) deficiency, residual insecticide spraying of household walls, and presence of sparse forest or rice paddies around the house; use of bed nets was not protective [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Most cases of <em>P. knowlesi</em> infection occur in adults [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18,22,23\" class=\"abstract_t\">18,22,23</a>]; children &lt;15 years accounted for only 9 percent of all <em>P. knowlesi</em> cases in Sabah, Malaysia, between 2010 and 2014 [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18\" class=\"abstract_t\">18</a>].</p><p>Travelers from nonendemic countries have acquired <em>P. knowlesi</em> infection in Malaysia, Thailand, Indonesia, and the Philippines [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/17\" class=\"abstract_t\">17</a>]. The majority of these cases have occurred in men who have spent time in forested regions. (See <a href=\"topic.htm?path=diseases-potentially-acquired-by-travel-to-southeast-asia\" class=\"medical medical_review\">&quot;Diseases potentially acquired by travel to Southeast Asia&quot;</a>.)</p><p>Transfusion-transmitted <em>P. knowlesi</em> malaria has been reported in Malaysia [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H2574693641\"><span class=\"h2\">Life cycle</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anopheline mosquitoes become infected with <em>P. knowlesi </em>parasites after ingesting sexual-stage parasites from infected macaque monkeys. The life cycle of <em>P. knowlesi</em> infection in humans begins when a female anopheline mosquito injects saliva containing sporozoites during a human blood meal (<a href=\"image.htm?imageKey=ID%2F115650\" class=\"graphic graphic_figure graphicRef115650 \">figure 2</a>). The sporozoites travel through the host's bloodstream to the liver, where they invade hepatocytes, undergo asexual replication, and develop into schizonts. Hepatic schizonts rupture and release thousands of daughter merozoites into the bloodstream, causing fever and an inflammatory response. <em>P. knowlesi</em> does not form latent hypnozoite stages.</p><p>Merozoites then invade erythrocytes where they develop into young ring parasites and then trophozoites, which undergo further asexual multiplication to form schizonts, containing numerous merozoites. The infected erythrocyte then ruptures, releasing merozoites, which reinvade uninfected erythrocytes, completing the first erythrocytic replication cycle. Within the erythrocyte, some of the merozoites develop into male and female gametocytes. In nonhuman primates (naturally) and human primates (at least experimentally) these gametocytes are taken up by a female mosquito and undergo sexual replication within the midgut of the mosquito to complete the life cycle.</p><p>The erythrocytic phase of the <em>P. knowlesi</em> life cycle lasts 24 hours, which is the shortest duration of any human malaria species. Therefore, patients with <em>P. knowlesi </em>experience daily fever spikes, and high parasitemia may develop rapidly.</p><p class=\"headingAnchor\" id=\"H1765424253\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The spectrum of clinical disease due to <em>P. knowlesi</em> infection ranges from asymptomatic infection to severe disease. Most patients have uncomplicated disease; severe disease occurs in 9 to 29 percent of adults but has not been observed in children [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/22,23,25\" class=\"abstract_t\">22,23,25</a>]. Fatal infection can occur, particularly in the setting of delayed treatment.</p><p>The incubation period of <em>P. knowlesi</em> infection is usually 8 to 12 days (range of 3 to 27 days) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/26-28\" class=\"abstract_t\">26-28</a>]. Parasites normally appear in the blood several days after the initial temperature rise. In a study of experimental mosquito infection, pre-patent periods (time to detectable parasitemia) of 9 to 12 days were reported [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/20\" class=\"abstract_t\">20</a>]. In hospital-based studies, the average duration of fever prior to presentation is five days [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>].</p><p class=\"headingAnchor\" id=\"H2082101697\"><span class=\"h2\">Nonpregnant adults</span></p><p class=\"headingAnchor\" id=\"H3155318781\"><span class=\"h3\">Uncomplicated infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For purposes of clinical management, uncomplicated <em>P. knowlesi</em> malaria is defined as clinical illness with parasitemia <span class=\"nowrap\">&lt;20,000/uL</span> and no features of severe malaria. (See <a href=\"#H2178070831\" class=\"local\">'Severe infection'</a> below.)</p><p>Clinical manifestations of <em>P. knowlesi</em> infection include fever (100 percent), chills, headache (92 percent), myalgia, nausea (56 percent), abdominal pain (31 to 51 percent), vomiting (32 percent), diarrhea, and cough (52 percent) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25,29\" class=\"abstract_t\">23,25,29</a>]. Physical findings include fever, tachycardia, and tachypnea. Splenomegaly and hepatomegaly are present in 15 to 33 percent and 24 to 40 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>].</p><p>Neurologic manifestations are rare in <em>P. knowlesi</em> infection. In the two case series including 237 patients with <em>P. knowlesi</em> infection (including 48 with severe disease), none had unarousable coma or seizures [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25,29\" class=\"abstract_t\">23,25,29</a>]. Case reports of coma or focal neurologic signs have been described [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18,23\" class=\"abstract_t\">18,23</a>]; however, absence of neuroimaging, lumbar puncture, and other diagnostic workup precluded exclusion of alternative diagnoses.</p><p>Retinopathy has been described in association with <em>P. knowlesi</em> infection. In one series including 44 patients with <em>P. knowlesi</em> infection, retinal hemorrhages were observed in 18 percent of cases and were associated with thrombocytopenia [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/30\" class=\"abstract_t\">30</a>]. However, the characteristic retinal whitening seen in severe falciparum malaria has not been observed in knowlesi malaria.</p><p class=\"headingAnchor\" id=\"H2178070831\"><span class=\"h3\">Severe infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Criteria for severe <em>P. knowlesi</em> infection are summarized in the table (<a href=\"image.htm?imageKey=ID%2F115654\" class=\"graphic graphic_table graphicRef115654 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7,25,31,32\" class=\"abstract_t\">7,25,31,32</a>]. Parasite count <span class=\"nowrap\">&gt;100,000/microL</span> is a strong independent risk factor for developing complications of severe <em>P. knowlesi</em> malaria [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/6\" class=\"abstract_t\">6</a>]. In one study including 130 patients with <em>P. knowlesi</em> infection, risk of severe illness increased 11-fold with parasitemia &gt;20 <span class=\"nowrap\">000/microL</span> and 28-fold with parasitemia &gt;100 <span class=\"nowrap\">000/microL</span> [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25\" class=\"abstract_t\">25</a>]. The likelihood of hyperparasitemia correlates with age; older adults have higher parasitemias and thus are at greater risk of severe disease [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/6,25\" class=\"abstract_t\">6,25</a>].</p><p>Clinical manifestations of severe disease include jaundice, acute kidney injury, respiratory distress, and shock [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/13\" class=\"abstract_t\">13</a>]. Acute kidney injury (creatinine &gt;3 <span class=\"nowrap\">mg/dL</span> [265 <span class=\"nowrap\">micromol/L])</span> occurs in 30 to 94 percent of patients with severe disease [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25,33,34\" class=\"abstract_t\">23,25,33,34</a>]. Blackwater fever with acute kidney injury has been described [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25,33,35\" class=\"abstract_t\">25,33,35</a>]. Respiratory distress is associated with hyperparasitemia and occurs in 18 to 70 percent of patients with severe disease [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25,33,34\" class=\"abstract_t\">23,25,33,34</a>]. Thrombocytopenia may rarely be associated with significant bleeding [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/11,23,25,36,37\" class=\"abstract_t\">11,23,25,36,37</a>]. Concurrent gram-negative bacteremia has been observed in severe <em>P. knowlesi</em> infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/33,38\" class=\"abstract_t\">33,38</a>].</p><p>The case-fatality rate of <em>P. knowlesi</em> malaria was estimated at 0.3 percent in one study; earlier diagnosis and use of <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> therapy were associated with lower case-fatality rates [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18\" class=\"abstract_t\">18</a>]. Death due to <em>P. knowlesi</em> infection occurs most commonly in older adults [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/11,18,23,33,38\" class=\"abstract_t\">11,18,23,33,38</a>]. Metabolic acidosis has been observed in most fatal cases [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/11,18,38\" class=\"abstract_t\">11,18,38</a>].</p><p class=\"headingAnchor\" id=\"H3511702746\"><span class=\"h3\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Routine laboratory investigations include hematologic studies and assessment of renal function, liver function, and acid-base status.</p><p>Anemia (hemoglobin &lt;10 <span class=\"nowrap\">g/dL)</span> occurs in 5 to 28 percent of cases [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>]. Severe anemia (&lt;7 <span class=\"nowrap\">g/dL)</span> is uncommon; in one series, severe anemia was observed in only 1.5 percent of cases overall and in only 5 percent of those with severe malaria [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>].</p><p>Thrombocytopenia (platelet count &lt;150 x 10<sup>3</sup><span class=\"nowrap\">/microL)</span> occurs routinely in <em>P. knowlesi </em>malaria. In two large series including 237 adults hospitalized with knowlesi malaria, thrombocytopenia occurred in 98 percent of cases; platelet count &lt;50 x 10<sup>3</sup><span class=\"nowrap\">/microL</span> occurred in 29 to 60 percent of cases [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>]. Platelet counts generally recover quickly, and bleeding occurs in only 5 percent of those with severe malaria [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>]. Hematemesis, however, has been observed in patients with severe disease [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/11,25,36,39\" class=\"abstract_t\">11,25,36,39</a>]. Absence of thrombocytopenia has been observed in some asplenic patients, suggesting a role of the spleen in platelet destruction or clearance [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/24,25,35,39\" class=\"abstract_t\">24,25,35,39</a>].</p><p>White blood cell counts are usually normal; neutrophilia has been observed in severe disease [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/6,25\" class=\"abstract_t\">6,25</a>].</p><p>Coagulation studies may be abnormal. In one series of patients requiring tertiary hospital admission, including 22 patients with severe disease, significant elevations of the prothrombin and partial thromboplastin times were observed in 32 percent of cases, although none had clinically important bleeding [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/33\" class=\"abstract_t\">33</a>].</p><p>Acute kidney injury (creatinine &gt;3 <span class=\"nowrap\">mg/dL</span> [265 <span class=\"nowrap\">micromol/L])</span> is common, particularly in severe disease. In two series including patients with severe knowlesi malaria, acute kidney injury occurred in 24 to 54 percent of patients [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25,33\" class=\"abstract_t\">25,33</a>]. Metabolic acidosis occurs in 11 to 32 percent of cases [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25,33\" class=\"abstract_t\">25,33</a>].</p><p>Mild elevations of liver transaminases are common [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>]. In two series, hyperbilirubinemia (&gt;2.46 <span class=\"nowrap\">mg/dL</span> [&gt;42 <span class=\"nowrap\">micromol/L])</span> was observed in 3 percent of hospital presentations and in 53 percent of patients with severe infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>].</p><p class=\"headingAnchor\" id=\"H2936852948\"><span class=\"h2\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. knowlesi</em> infection in children is uncommon [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18,22,23\" class=\"abstract_t\">18,22,23</a>]. In one study including 4225 cases in Sabah, Malaysia, between 2010 and 2014, 9 percent occurred in children [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18\" class=\"abstract_t\">18</a>].</p><p>Children typically present with fever [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/40\" class=\"abstract_t\">40</a>]. Thrombocytopenia is almost universal, and mild anemia is common [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/40\" class=\"abstract_t\">40</a>]. Parasitemia is usually low [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/13,25\" class=\"abstract_t\">13,25</a>].</p><p>Severe disease has not been observed in children, and no pediatric deaths have been reported [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18,40,41\" class=\"abstract_t\">18,40,41</a>].</p><p class=\"headingAnchor\" id=\"H2234807279\"><span class=\"h2\">Pregnant women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. knowlesi</em> infection during pregnancy appears to be relatively rare; thus far, only five cases have been reported [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/33,42\" class=\"abstract_t\">33,42</a>]. Adverse maternal and infant outcomes have been described, including severe maternal malaria, fetal loss, and low birth weight.</p><p class=\"headingAnchor\" id=\"H2673827734\"><span class=\"h2\">Asymptomatic infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Asymptomatic infection has been observed in endemic areas among adults and children [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/15,16,43,44\" class=\"abstract_t\">15,16,43,44</a>]. The proportion of asymptomatic individuals in northeastern Sabah, Malaysia, has been estimated to be 7 percent [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/44\" class=\"abstract_t\">44</a>].</p><p class=\"headingAnchor\" id=\"H1623954686\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. knowlesi</em> malaria should be suspected in the setting of febrile illness after exposure to regions where <em>P. knowlesi</em> malaria is endemic (<a href=\"image.htm?imageKey=ID%2F115652\" class=\"graphic graphic_figure graphicRef115652 \">figure 1</a>).</p><p>The approach to diagnosis of <em>P. knowlesi</em> malaria consists of microscopy to guide immediate clinical management, followed by confirmatory testing with polymerase chase reaction (PCR) in a reference laboratory if feasible. PCR is the gold standard diagnostic tool with excellent sensitivity and specificity [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/45\" class=\"abstract_t\">45</a>].</p><p>Microscopy is a sensitive tool for the diagnosis of malaria and may be used to detect all species; it allows determination of parasitemia and the life cycle stages present (<a href=\"image.htm?imageKey=ID%2F53291\" class=\"graphic graphic_table graphicRef53291 \">table 2</a>). However, microscopy cannot be reliably used for distinguishing <em>P. knowlesi</em> from other species (<a href=\"image.htm?imageKey=ID%2F80296\" class=\"graphic graphic_figure graphicRef80296 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/4,38,46,47\" class=\"abstract_t\">4,38,46,47</a>]. The blood stages of <em>P. knowlesi</em> resemble <em>P. malariae</em> and the ring stages resemble <em>P. falciparum</em>.</p><p>Because <em>P. knowlesi</em> may be indistinguishable from <em>P. malariae</em> on microscopy, patients with exposure to regions where <em>P. knowlesi</em> malaria is endemic and microscopy findings resembling <em>P. malariae</em> should be treated for <em>P. knowlesi</em> infection. (See <a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">&quot;Diagnosis of malaria&quot;</a> and <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae#H15\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae&quot;, section on 'Diagnosis'</a>.)</p><p>The limit of detection of microscopy is about 20 <span class=\"nowrap\">parasites/microL</span> in expert hands. It would be unlikely for a patient to present with acute illness and parasitemia below the limit of detection of microscopy. Competent microscopy requires ongoing training and evaluation and proper supplies and equipment.</p><p>Rapid diagnostic tests (RDTs) are useful for excluding <em>P. falciparum</em> infection but have poor sensitivity for detection of <em>P. knowlesi</em> infection, particularly at the low parasite densities commonly causing clinical disease [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/48-50\" class=\"abstract_t\">48-50</a>]. Available RDTs are unable to distinguish <em>P. knowlesi</em> from other non-falciparum species [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/48,49\" class=\"abstract_t\">48,49</a>].</p><p class=\"headingAnchor\" id=\"H3592481452\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of malaria is outlined separately. (See <a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children#H19\" class=\"medical medical_review\">&quot;Clinical manifestations of malaria in nonpregnant adults and children&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H1359240066\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, all adults with known or suspected <em>P. knowlesi</em> infection should be admitted to hospital for management, because of the significant risk of severe disease at relatively low parasitemia and the risk of developing complications after commencement of treatment [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23,25\" class=\"abstract_t\">23,25</a>]. We are in agreement with Malaysian Ministry of Health Guidelines which require hospital admission for all adults &gt;40 years of age [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/6,25\" class=\"abstract_t\">6,25</a>].</p><p class=\"headingAnchor\" id=\"H1133672839\"><span class=\"h2\">Adults</span></p><p class=\"headingAnchor\" id=\"H4094566455\"><span class=\"h3\">Uncomplicated infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For clinical purposes, uncomplicated <em>P. knowlesi</em> malaria is defined as clinical illness with parasitemia &lt;20,000 <span class=\"nowrap\">parasites/microL</span> and no features of severe malaria (<a href=\"image.htm?imageKey=ID%2F115654\" class=\"graphic graphic_table graphicRef115654 \">table 1</a>).</p><p>The preferred therapy for treatment of uncomplicated <em>P. knowlesi</em> infection consists of an oral artemisinin combination therapy (ACT) regimen [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Patients unable to tolerate oral intake should be treated with parenteral therapy as described below. (See <a href=\"#H889853449\" class=\"local\">'Severe infection'</a> below.)</p><p>ACTs are superior to <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> for treatment of drug-resistant <em>P. falciparum</em> and <em>P. vivax</em> malaria found in coendemic regions [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/51,52\" class=\"abstract_t\">51,52</a>]. Given that, in <em>P. knowlesi</em>&ndash;endemic areas, <em>P. falciparum</em> and <em>P. vivax</em> are commonly misdiagnosed as <em>P. knowlesi</em>, use of chloroquine for the treatment of microscopy-diagnosed &quot;<em>P. knowlesi</em>&quot; malaria may result in inadvertent administration of chloroquine for misdiagnosed <em>P. falciparum</em> or <em>P. vivax </em>infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/15,16,47\" class=\"abstract_t\">15,16,47</a>]. ACTs for treatment of uncomplicated <em>P. knowlesi</em> malaria are summarized in the table (<a href=\"image.htm?imageKey=ID%2F107830\" class=\"graphic graphic_table graphicRef107830 \">table 3</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">Artemether-lumefantrine</a> is the preferred ACT for treatment of uncomplicated <em>P. knowlesi</em> malaria, given its excellent efficacy, tolerability, and wide availability [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25,33\" class=\"abstract_t\">25,33</a>]. In a randomized trial including 123 patients with uncomplicated <em>P. knowlesi</em> infection treated with artemether-lumefantrine or <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a>, those treated with artemether-lumefantrine had faster parasite clearance (18 versus 24 hours; p = 0.02) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other ACTs used successfully for treatment of uncomplicated <em>P. knowlesi</em> malaria include artesunate-mefloquine and dihydroartemisinin-piperaquine. In a randomized trial including 252 patients with uncomplicated <em>P. knowlesi</em> malaria treated with artesunate-mefloquine or <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a>, those treated with artesunate-mefloquine had faster parasite clearance (18 versus 24 hours), faster fever clearance (11 versus 14 hours), and lower risk of anemia within 28 days (71 versus 83 percent) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/22\" class=\"abstract_t\">22</a>]. Successful use of dihydroartemisinin-piperaquine has been described in a single report [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/54\" class=\"abstract_t\">54</a>].</p><p/><p>Alternative drugs for treatment of uncomplicated <em>P. knowlesi</em> malaria include <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/22,31,51\" class=\"abstract_t\">22,31,51</a>] and <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">atovaquone-proguanil</a> [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/55-58\" class=\"abstract_t\">55-58</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> is efficacious for treatment of <em>P. knowlesi</em> infection but has been associated with slower parasite clearance times and a higher frequency of anemia than ACTs [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/10,22,31,53\" class=\"abstract_t\">10,22,31,53</a>]. Adult dosing of chloroquine consists of a total dose of 25 mg <span class=\"nowrap\">base/kg</span> administered as 10 mg <span class=\"nowrap\">base/kg</span> orally on day 1, followed by 10 mg <span class=\"nowrap\">base/kg</span> orally on day 2, and 5 mg <span class=\"nowrap\">base/kg</span> on day 3. Minor side effects of chloroquine (including bitter taste, gastrointestinal disturbances, dizziness, blurred vision, and headache) may be alleviated by taking the drug with food. (See <a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">&quot;Antimalarial drugs: An overview&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">Hydroxychloroquine</a>, the hydroxyl analogue of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a>, has similar properties and activity to chloroquine and in vitro has similar efficacy against chloroquine-sensitive <em>P. falciparum </em>[<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/59\" class=\"abstract_t\">59</a>]. It is likely to be effective; its use for the treatment of <em>P. knowlesi</em> malaria has not been described.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">Atovaquone-proguanil</a> has been used for the treatment of uncomplicated <em>P. knowlesi</em> malaria in returned travelers, with rapid recovery reported in all cases [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/55-58\" class=\"abstract_t\">55-58</a>]. Adult dosing of atovaquone-proguanil consists of four adult tabs (250 mg <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">atovaquone</a><span class=\"nowrap\">/100</span> mg proguanil) orally once daily for three days.</p><p/><p>Oral <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> has been used successfully to treat uncomplicated <em>P. knowlesi</em> malaria; however, we do not recommend its use (with <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>) as first-line treatment of uncomplicated <em>P. knowlesi</em> malaria, given significantly slower parasite clearance times than with ACT [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/33\" class=\"abstract_t\">33</a>].</p><p>Successful treatment of uncomplicated <em>P. knowlesi</em> malaria with <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a> has been described [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/60,61\" class=\"abstract_t\">60,61</a>]. However, treatment failures have been reported in rhesus macaques [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/62,63\" class=\"abstract_t\">62,63</a>]. We are in agreement with the World Health Organization, which favors use of mefloquine as an artemisinin partner drug and discourages mefloquine monotherapy [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7\" class=\"abstract_t\">7</a>].</p><p>No molecular evidence of drug resistance in <em>P. knowlesi</em> has been identified to date [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/14,64-66\" class=\"abstract_t\">14,64-66</a>].</p><p class=\"headingAnchor\" id=\"H889853449\"><span class=\"h3\">Severe infection</span></p><p class=\"headingAnchor\" id=\"H1117334877\"><span class=\"h4\">Antimalarial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial management of patients with features of severe <em>P. knowlesi</em> malaria (<a href=\"image.htm?imageKey=ID%2F115654\" class=\"graphic graphic_table graphicRef115654 \">table 1</a>) or with parasitemia &gt;20,000 <span class=\"nowrap\">parasites/microL</span> consists of parenteral therapy [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/17,32\" class=\"abstract_t\">17,32</a>]. Parenteral therapy is also warranted for patients unable to tolerate oral intake. (See <a href=\"#H2178070831\" class=\"local\">'Severe infection'</a> above.)</p><p>Treatment of severe malaria (caused by any species) consists of parenteral <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7\" class=\"abstract_t\">7</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study at a tertiary hospital in Malaysia including 16 patients with severe <em>P. knowlesi</em> malaria treated with intravenous <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> (before intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> was available), 31 percent of patients died [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/33\" class=\"abstract_t\">33</a>]. In a subsequent prospective study at the same hospital including 38 patients with severe <em>P. knowlesi</em> malaria treated with intravenous artesunate, all patients survived [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25\" class=\"abstract_t\">25</a>]. Following statewide implementation of intravenous artesunate in Malaysia, the case-fatality rate due to <em>P. knowlesi</em> malaria between 2010 and 2014 fell from 9.2 to 1.<span class=\"nowrap\">6/1000</span> case notifications [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18\" class=\"abstract_t\">18</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> for treatment of severe <em>P. knowlesi </em>malaria is also supported by randomized trials in Southeast Asian adults and children [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/67\" class=\"abstract_t\">67</a>] and African children [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/68\" class=\"abstract_t\">68</a>] demonstrating reduced mortality with intravenous artesunate compared with intravenous <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> for the treatment of severe <em>P. falciparum</em> malaria.</p><p/><p>The optimal approach for treatment of patients with parasitemia &gt;20,000 <span class=\"nowrap\">parasites/microL</span> in the absence of other evidence of severe disease is uncertain. For such patients, we favor at least one dose of intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a>, given the increased risk of severe malaria associated with moderately high parasite counts. In one study including 130 patients with <em>P. knowlesi</em> infection, presence of parasitemia &gt;20,000 <span class=\"nowrap\">parasites/microL</span> was associated with an 11-fold risk of severe infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25\" class=\"abstract_t\">25</a>]. Another study noted that patients with parasitemia &ge;35,000 <span class=\"nowrap\">parasites/microL</span> were more likely to develop complications (odds ratio [OR] 9.93) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/34\" class=\"abstract_t\">34</a>].</p><p>For patients meeting criteria for severe disease, intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> should be administered for a minimum of three doses; dosing is summarized in the table (<a href=\"image.htm?imageKey=ID%2F79194\" class=\"graphic graphic_table graphicRef79194 \">table 4</a>). Intravenous therapy should be followed by a three-day course of oral ACT once oral intake is tolerated. (See <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a>.)</p><p>If intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> is not available, intravenous <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> is an acceptable alternative therapy; dosing is summarized in the table (<a href=\"image.htm?imageKey=ID%2F79194\" class=\"graphic graphic_table graphicRef79194 \">table 4</a>). (See <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a>.)</p><p>Patients treated with intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> should be monitored for delayed hemolytic anemia, with repeat hemoglobin testing at 7 and 14 days after treatment [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7,69,70\" class=\"abstract_t\">7,69,70</a>].</p><p>Patients treated with parenteral therapy because of inability to tolerate oral intake (in the absence of other criteria for severe malaria) may be switched from intravenous therapy to a three-day course of oral ACT regimen as soon as oral intake is tolerated.</p><p class=\"headingAnchor\" id=\"H3331312955\"><span class=\"h4\">Supportive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Severe <em>P. knowlesi</em> malaria may be associated with multiorgan failure requiring intensive supportive care, including inotropic and ventilatory support [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/33\" class=\"abstract_t\">33</a>] and hemodialysis for acute kidney injury [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25,33\" class=\"abstract_t\">25,33</a>].</p><p>Intravenous fluids should be administered conservatively [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/71\" class=\"abstract_t\">71</a>]. There have been no clinical trials to guide intravenous fluid management in <em>P. knowlesi</em> malaria; our approach is extrapolated from studies of severe <em>P. falciparum</em> malaria in which liberal administration of intravenous fluids has been shown to be deleterious [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/71,72\" class=\"abstract_t\">71,72</a>] and conservative fluid regimens have been shown to be safe [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/73\" class=\"abstract_t\">73</a>].</p><p>Empiric broad-spectrum intravenous antibiotics are commonly administered in severe <em>P. knowlesi</em> malaria until blood cultures are negative [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25\" class=\"abstract_t\">25</a>].</p><p>Platelet counts generally recover rapidly after commencement of antimalarial treatment [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H3071226439\"><span class=\"h2\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to selection of antimalarial therapy for children with uncomplicated <em>P. knowlesi</em> infection is the same as for adults. (See <a href=\"#H3155318781\" class=\"local\">'Uncomplicated infection'</a> above.)</p><p>Dosing of oral ACT regimens is summarized in the table (<a href=\"image.htm?imageKey=ID%2F107830\" class=\"graphic graphic_table graphicRef107830 \">table 3</a>). Pediatric dosing of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> consists of 10 mg <span class=\"nowrap\">base/kg</span> orally immediately, followed by 5 mg <span class=\"nowrap\">base/kg</span> orally at 6, 24, and 48 hours (total dose 25 mg <span class=\"nowrap\">base/kg;</span> maximum total dose 1500 mg base [=2500 mg salt]). Pediatric dosing of <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">atovaquone</a> is weight-based (5 to 8 kg: 2 pediatric tabs orally once daily for three days; 9 to 10 kg: 3 pediatric tabs orally once daily for three days; 11 to 20 kg: 1 adult tab orally once daily for three days; 21 to 30 kg: 2 adult tabs orally once daily for three days; 31 to 40 kg: 3 adult tabs orally once daily for three days).</p><p><a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">Hydroxychloroquine</a> has similar properties and activity to <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> and in vitro has similar efficacy against chloroquine-sensitive <em>P. falciparum </em>[<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/59\" class=\"abstract_t\">59</a>]. It is likely to be effective; its use for the treatment of <em>P. knowlesi</em> malaria has not been described.</p><p>Oral <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> has been used successfully to treat uncomplicated <em>P. knowlesi</em> malaria in children [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/40\" class=\"abstract_t\">40</a>]; however, we do not recommend its use as first-line treatment of uncomplicated <em>P. knowlesi</em> malaria, given significantly slower parasite clearance times than with ACT [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/33\" class=\"abstract_t\">33</a>].</p><p>Use of intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> is warranted for children who do not tolerate oral intake [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25,67,68\" class=\"abstract_t\">25,67,68</a>]. As soon as oral intake is tolerated, treatment may be switched from intravenous therapy to a three-day course of oral ACT regimen.</p><p>Severe disease due to <em>P. knowlesi</em> infection in children has not been described; therefore, there is no experience regarding use of intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> for this indication. However, children with severe malaria from any species warrant treatment with intravenous artesunate; further principles for management of severe malaria in children are discussed separately. (See <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1354308628\"><span class=\"h2\">Pregnant women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of pregnant women with uncomplicated <em>P. knowlesi</em> malaria in the second or third trimester consists of an oral ACT regimen; <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> is an acceptable alternative [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7\" class=\"abstract_t\">7</a>]. Treatment of pregnant women with uncomplicated <em>P. knowlesi</em> malaria in the first trimester consists of chloroquine. Drug dosing is summarized in the table (<a href=\"image.htm?imageKey=ID%2F107719\" class=\"graphic graphic_table graphicRef107719 \">table 5</a>).</p><p>Pregnant women with severe malaria (due to any species) should be treated with intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a>, regardless of trimester [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=treatment-of-severe-malaria#H25\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;, section on 'Pregnancy'</a>.)</p><p>If there is any doubt as to the species diagnosis, treatment for <em>P. falciparum</em> infection should be administered [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=prevention-and-treatment-of-malaria-in-pregnant-women#H3\" class=\"medical medical_review\">&quot;Prevention and treatment of malaria in pregnant women&quot;, section on 'P. falciparum'</a>.)</p><p class=\"headingAnchor\" id=\"H2633272727\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-malaria\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Malaria&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1556270334\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Plasmodium knowlesi</em> is a simian malaria parasite; the natural hosts are macaques. Human cases of knowlesi malaria have been reported throughout Southeast Asia (<a href=\"image.htm?imageKey=ID%2F115652\" class=\"graphic graphic_figure graphicRef115652 \">figure 1</a>). (See <a href=\"#H1863622304\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Humans are incidentally infected with <em>P. knowlesi</em> when bitten by a mosquito vector that has fed from a macaque reservoir host (<a href=\"image.htm?imageKey=ID%2F115650\" class=\"graphic graphic_figure graphicRef115650 \">figure 2</a>). Human <em>P. knowlesi </em>infection is generally acquired in forest or forest-fringe areas; those at risk include farmers, plantation workers, and individuals undertaking other activities in forested areas. Most cases of <em>P. knowlesi</em> infection occur in adults. (See <a href=\"#H3881578288\" class=\"local\">'Transmission and risk factors for infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The spectrum of clinical disease due to <em>P. knowlesi</em> infection ranges from asymptomatic infection to severe disease. The incubation period of <em>P. knowlesi</em> infection is usually 8 to 12 days. Clinical manifestations of <em>P. knowlesi</em> infection include fever, chills, headache, myalgia, nausea, abdominal pain, vomiting, diarrhea, and cough. Physical findings include fever, tachycardia, and tachypnea; splenomegaly and hepatomegaly are observed in some cases. Most patients have uncomplicated disease, defined as clinical illness with parasitemia <span class=\"nowrap\">&lt;20,000/uL</span> and no features of severe malaria. (See <a href=\"#H1765424253\" class=\"local\">'Clinical manifestations'</a> above and <a href=\"#H3155318781\" class=\"local\">'Uncomplicated infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe disease occurs in a minority of adults but has not been observed in children. Clinical manifestations of severe disease include jaundice, acute kidney injury, respiratory distress, and shock. Criteria for severe <em>P. knowlesi</em> infection are summarized in the table (<a href=\"image.htm?imageKey=ID%2F115654\" class=\"graphic graphic_table graphicRef115654 \">table 1</a>). (See <a href=\"#H2178070831\" class=\"local\">'Severe infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. knowlesi</em> malaria should be suspected in the setting of febrile illness after exposure to regions where <em>P. knowlesi</em> malaria is endemic. The approach to diagnosis consists of microscopy (to guide immediate clinical management), followed by confirmatory testing with polymerase chase reaction in a reference laboratory (if feasible). Microscopy cannot be reliably used for distinguishing <em>P. knowlesi</em> from other species (<a href=\"image.htm?imageKey=ID%2F80296\" class=\"graphic graphic_figure graphicRef80296 \">figure 3</a>). Therefore, patients with relevant epidemiologic exposure and microscopy findings resembling <em>P. malariae</em> should be treated for <em>P. knowlesi</em> infection. Rapid diagnostic tests are useful for excluding <em>P. falciparum</em> infection but have poor sensitivity for detection of <em>P. knowlesi</em> infection. (See <a href=\"#H1623954686\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adults with known or suspected <em>P. knowlesi</em> infection should be admitted to the hospital for management because of the significant risk of severe disease at relatively low parasitemia and the risk of developing complications after commencement of treatment. (See <a href=\"#H1359240066\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment of uncomplicated <em>P. knowlesi</em> infection, we suggest an oral artemisinin combination therapy (ACT) regimen (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>); regimens are summarized in the table (<a href=\"image.htm?imageKey=ID%2F107830\" class=\"graphic graphic_table graphicRef107830 \">table 3</a>). (See <a href=\"#H3155318781\" class=\"local\">'Uncomplicated infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial treatment of severe malaria consists of parenteral therapy. We suggest intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> (in areas where intravenous artesunate of reliable quality is readily available) rather than intravenous <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> (<a href=\"grade.htm?i=4\" class=\"grade\">Grade 2A</a>); dosing is summarized in the table (<a href=\"image.htm?imageKey=ID%2F79194\" class=\"graphic graphic_table graphicRef79194 \">table 4</a>). Intravenous therapy should be followed by a three-day course of an oral ACT regimen once oral intake is tolerated. (See <a href=\"#H889853449\" class=\"local\">'Severe infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment of patients with parasitemia &gt;20,000 <span class=\"nowrap\">parasites/microL</span> in the absence of other evidence for severe disease, we suggest at least one dose of intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>), given the increased risk of severe malaria associated with moderately high parasite counts. (See <a href=\"#H889853449\" class=\"local\">'Severe infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. knowlesi</em> does not form hypnozoite liver stages; therefore, anti-relapse therapy is not required. (See <a href=\"#H2574693641\" class=\"local\">'Life cycle'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/1\" class=\"nounderline abstract_t\">Napier LE, Campbell HGM. Observations on a Plasmodium Infection Which Causes H&aelig;moglobinuria in Certain Species of Monkey. Ind Med Gaz 1932; 67:246.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/2\" class=\"nounderline abstract_t\">Shearer FM, Huang Z, Weiss DJ, et al. Estimating Geographical Variation in the Risk of Zoonotic Plasmodium knowlesi Infection in Countries Eliminating Malaria. PLoS Negl Trop Dis 2016; 10:e0004915.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/3\" class=\"nounderline abstract_t\">Grigg MJ, Cox J, William T, et al. Individual-level factors associated with the risk of acquiring human Plasmodium knowlesi malaria in Malaysia: a case-control study. Lancet Planet Health 2017; 1:e97.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/4\" class=\"nounderline abstract_t\">William T, Jelip J, Menon J, et al. Changing epidemiology of malaria in Sabah, Malaysia: increasing incidence of Plasmodium knowlesi. Malar J 2014; 13:390.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/5\" class=\"nounderline abstract_t\">William T, Rahman HA, Jelip J, et al. Increasing incidence of Plasmodium knowlesi malaria following control of P. falciparum and P. vivax Malaria in Sabah, Malaysia. PLoS Negl Trop Dis 2013; 7:e2026.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/6\" class=\"nounderline abstract_t\">Barber BE, Grigg MJ, William T, et al. Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Plasmodium knowlesi and Plasmodium falciparum Malaria. J Infect Dis 2017; 215:1908.</a></li><li class=\"breakAll\">Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization, 2015. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1&amp;ua=1 (Accessed on October 22, 2015).</li><li class=\"breakAll\">Ministry of Health Malaysia. Management Guidelines of Malaria in Malaysia Vector Borne Disease Sector, Disease Control Division, Ministry of Health, Malaysia 2014. http://www.moh.gov.my/english.php/pages/view/118 (Accessed on September 07, 2017).</li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/9\" class=\"nounderline abstract_t\">CHIN W, CONTACOS PG, COATNEY GR, KIMBALL HR. A NATURALLY ACQUITED QUOTIDIAN-TYPE MALARIA IN MAN TRANSFERABLE TO MONKEYS. Science 1965; 149:865.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/10\" class=\"nounderline abstract_t\">Singh B, Kim Sung L, Matusop A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004; 363:1017.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/11\" class=\"nounderline abstract_t\">Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/12\" class=\"nounderline abstract_t\">Moyes CL, Shearer FM, Huang Z, et al. Predicting the geographical distributions of the macaque hosts and mosquito vectors of Plasmodium knowlesi malaria in forested and non-forested areas. Parasit Vectors 2016; 9:242.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/13\" class=\"nounderline abstract_t\">Singh B, Daneshvar C. Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 2013; 26:165.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/14\" class=\"nounderline abstract_t\">Tyagi RK, Das MK, Singh SS, Sharma YD. Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections. J Antimicrob Chemother 2013; 68:1081.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/15\" class=\"nounderline abstract_t\">Lubis IND, Wijaya H, Lubis M, et al. Contribution of Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera, Indonesia. J Infect Dis 2017; 215:1148.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/16\" class=\"nounderline abstract_t\">Herdiana H, Cotter C, Coutrier FN, et al. Malaria risk factor assessment using active and passive surveillance data from Aceh Besar, Indonesia, a low endemic, malaria elimination setting with Plasmodium knowlesi, Plasmodium vivax, and Plasmodium falciparum. Malar J 2016; 15:468.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/17\" class=\"nounderline abstract_t\">Barber BE, Grigg MJ, William T, et al. The Treatment of Plasmodium knowlesi Malaria. Trends Parasitol 2017; 33:242.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/18\" class=\"nounderline abstract_t\">Rajahram GS, Barber BE, William T, et al. Falling Plasmodium knowlesi Malaria Death Rate among Adults despite Rising Incidence, Sabah, Malaysia, 2010-2014. Emerg Infect Dis 2016; 22:41.</a></li><li class=\"breakAll\">Sarawak State Health Department. Official Portal: Sarawak State Health Department http://jknsarawak.moh.gov.my/en/modules/mastop_publish/?tac=164 (Accessed on September 08, 2017).</li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/20\" class=\"nounderline abstract_t\">Chin W, Contacos PG, Collins WE, et al. Experimental mosquito-transmission of Plasmodium knowlesi to man and monkey. Am J Trop Med Hyg 1968; 17:355.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/21\" class=\"nounderline abstract_t\">Barber BE, William T, Dhararaj P, et al. Epidemiology of Plasmodium knowlesi malaria in north-east Sabah, Malaysia: family clusters and wide age distribution. Malar J 2012; 11:401.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/22\" class=\"nounderline abstract_t\">Grigg MJ, William T, Menon J, et al. Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. Lancet Infect Dis 2016; 16:180.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/23\" class=\"nounderline abstract_t\">Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis 2009; 49:852.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/24\" class=\"nounderline abstract_t\">Bird EM, Parameswaran U, William T, et al. Transfusion-transmitted severe Plasmodium knowlesi malaria in a splenectomized patient with beta-thalassaemia major in Sabah, Malaysia: a case report. Malar J 2016; 15:357.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/25\" class=\"nounderline abstract_t\">Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013; 56:383.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/26\" class=\"nounderline abstract_t\">Knowles R, Das Gupta BM. A study of monkey-malaria and its experimental transmission to man. Ind Med Gaz 1932; 67:246.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/27\" class=\"nounderline abstract_t\">van Rooyen CE, Pile GR. OBSERVATIONS ON INFECTION BY PLASMODIUM KNOWLESI (APE MALARIA) IN THE TREATMENT OF GENERAL PARALYSIS OF THE INSANE. Br Med J 1935; 2:662.</a></li><li class=\"breakAll\">Milam DF, Coggeshall LT. Duration of Plasmodium knowlesi infections in man. Am J Trop Med Hyg. 1938;18:331-8.</li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/29\" class=\"nounderline abstract_t\">Daneshvar C, William T, Davis TME. Clinical features and management of Plasmodium knowlesi infections in humans. Parasitology 2018; 145:18.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/30\" class=\"nounderline abstract_t\">Govindasamy G, Barber BE, Ghani SA, et al. Retinal Changes in Uncomplicated and Severe Plasmodium knowlesi Malaria. J Infect Dis 2016; 213:1476.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/31\" class=\"nounderline abstract_t\">Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J 2010; 9:238.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/32\" class=\"nounderline abstract_t\">Severe malaria. Trop Med Int Health 2014; 19 Suppl 1:7.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/33\" class=\"nounderline abstract_t\">William T, Menon J, Rajahram G, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011; 17:1248.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/34\" class=\"nounderline abstract_t\">Willmann M, Ahmed A, Siner A, et al. Laboratory markers of disease severity in Plasmodium knowlesi infection: a case control study. Malar J 2012; 11:363.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/35\" class=\"nounderline abstract_t\">Barber BE, Grigg MJ, William T, et al. Intravascular haemolysis with haemoglobinuria in a splenectomized patient with severe Plasmodium knowlesi malaria. Malar J 2016; 15:462.</a></li><li class=\"breakAll\">Ninan T, Nalees K, Newin M, et al. Plasmodium knowlesi malaria infection in human. Brunei International Medical Journal. 2012;8(6):358-61.</li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/37\" class=\"nounderline abstract_t\">Lee CE, Adeeba K, Freigang G. Human Plasmodium knowlesi infections in Klang Valley, Peninsula Malaysia: a case series. Med J Malaysia 2010; 65:63.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/38\" class=\"nounderline abstract_t\">Rajahram GS, Barber BE, William T, et al. Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malar J 2012; 11:284.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/39\" class=\"nounderline abstract_t\">Boo YL, Lim HT, Chin PW, et al. A case of severe Plasmodium knowlesi in a splenectomized patient. Parasitol Int 2016; 65:55.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/40\" class=\"nounderline abstract_t\">Barber BE, William T, Jikal M, et al. Plasmodium knowlesi malaria in children. Emerg Infect Dis 2011; 17:814.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/41\" class=\"nounderline abstract_t\">Douglas NM, Lampah DA, Kenangalem E, et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med 2013; 10:e1001575; discussion e1001575.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/42\" class=\"nounderline abstract_t\">Barber BE, Bird E, Wilkes CS, et al. Plasmodium knowlesi malaria during pregnancy. J Infect Dis 2015; 211:1104.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/43\" class=\"nounderline abstract_t\">Marchand RP, Culleton R, Maeno Y, et al. Co-infections of Plasmodium knowlesi, P. falciparum, and P. vivax among Humans and Anopheles dirus Mosquitoes, Southern Vietnam. Emerg Infect Dis 2011; 17:1232.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/44\" class=\"nounderline abstract_t\">Fornace KM, Nuin NA, Betson M, et al. Asymptomatic and Submicroscopic Carriage of Plasmodium knowlesi Malaria in Household and Community Members of Clinical Cases in Sabah, Malaysia. J Infect Dis 2016; 213:784.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/45\" class=\"nounderline abstract_t\">Imwong M, Tanomsing N, Pukrittayakamee S, et al. Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P. knowlesi. J Clin Microbiol 2009; 47:4173.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/46\" class=\"nounderline abstract_t\">Lee KS, Cox-Singh J, Singh B. Morphological features and differential counts of Plasmodium knowlesi parasites in naturally acquired human infections. Malar J 2009; 8:73.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/47\" class=\"nounderline abstract_t\">Barber BE, William T, Grigg MJ, et al. Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J 2013; 12:8.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/48\" class=\"nounderline abstract_t\">Barber BE, William T, Grigg MJ, et al. Evaluation of the sensitivity of a pLDH-based and an aldolase-based rapid diagnostic test for diagnosis of uncomplicated and severe malaria caused by PCR-confirmed Plasmodium knowlesi, Plasmodium falciparum, and Plasmodium vivax. J Clin Microbiol 2013; 51:1118.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/49\" class=\"nounderline abstract_t\">Grigg MJ, William T, Barber BE, et al. Combining parasite lactate dehydrogenase-based and histidine-rich protein 2-based rapid tests to improve specificity for diagnosis of malaria Due to Plasmodium knowlesi and other Plasmodium species in Sabah, Malaysia. J Clin Microbiol 2014; 52:2053.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/50\" class=\"nounderline abstract_t\">Foster D, Cox-Singh J, Mohamad DS, et al. Evaluation of three rapid diagnostic tests for the detection of human infections with Plasmodium knowlesi. Malar J 2014; 13:60.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/51\" class=\"nounderline abstract_t\">Grigg MJ, William T, Menon J, et al. Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clin Infect Dis 2016; 62:1403.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/52\" class=\"nounderline abstract_t\">Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10:405.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/53\" class=\"nounderline abstract_t\">Grigg MJ, William T, Barber BE, et al. Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW. Clin Infect Dis 2018; 66:229.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/54\" class=\"nounderline abstract_t\">Setiadi W, Sudoyo H, Trimarsanto H, et al. A zoonotic human infection with simian malaria, Plasmodium knowlesi, in Central Kalimantan, Indonesia. Malar J 2016; 15:218.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/55\" class=\"nounderline abstract_t\">Figtree M, Lee R, Bain L, et al. Plasmodium knowlesi in human, Indonesian Borneo. Emerg Infect Dis 2010; 16:672.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/56\" class=\"nounderline abstract_t\">Ehrhardt J, Trein A, Kremsner P, Frank M. Plasmodium knowlesi and HIV co-infection in a German traveller to Thailand. Malar J 2013; 12:283.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/57\" class=\"nounderline abstract_t\">Hoosen A, Shaw MT. Plasmodium knowlesi in a traveller returning to New Zealand. Travel Med Infect Dis 2011; 9:144.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/58\" class=\"nounderline abstract_t\">Mackroth MS, Tappe D, Tannich E, et al. Rapid-Antigen Test Negative Malaria in a Traveler Returning From Thailand, Molecularly Diagnosed as Plasmodium knowlesi. Open Forum Infect Dis 2016; 3:ofw039.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/59\" class=\"nounderline abstract_t\">Warhurst DC, Steele JC, Adagu IS, et al. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 2003; 52:188.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/60\" class=\"nounderline abstract_t\">Bronner U, Divis PC, F&auml;rnert A, Singh B. Swedish traveller with Plasmodium knowlesi malaria after visiting Malaysian Borneo. Malar J 2009; 8:15.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/61\" class=\"nounderline abstract_t\">Abanyie FA, McCracken C, Kirwan P, et al. Ascaris co-infection does not alter malaria-induced anaemia in a cohort of Nigerian preschool children. Malar J 2013; 12:1.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/62\" class=\"nounderline abstract_t\">Tripathi R, Awasthi A, Dutta GP. Mefloquine resistance reversal action of ketoconazole - a cytochrome P450 inhibitor, against mefloquine-resistant malaria. Parasitology 2005; 130:475.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/63\" class=\"nounderline abstract_t\">Singh PP, Dutta GP. Antimalarial activity of mefloquine and chloroquine against blood induced Plasmodium knowlesi infection in rhesus monkeys. Indian J Med Res 1981; 73 Suppl:23.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/64\" class=\"nounderline abstract_t\">Grigg MJ, Barber BE, Marfurt J, et al. Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia. PLoS One 2016; 11:e0149519.</a></li><li class=\"breakAll\">Assefa S, Lim C, Preston MD, et al. Population genomic structure and adaptation in the zoonotic malaria parasite Plasmodium knowlesi. Proceedings of the National Academy of Sciences. 2015;112(42):13027-32.</li><li class=\"breakAll\">Fatih FA, Staines HM, Siner A, et al. Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malar J. 2013;12(425.10):1186.</li><li class=\"breakAll\">Dondorp A, Nosten F, Stepniewska K, Day N, White N, South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. The Lancet. 2005;366(9487):717-25.</li><li class=\"breakAll\">Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. The Lancet. 2010;376(9753):1647-57.</li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/69\" class=\"nounderline abstract_t\">Jaur&eacute;guiberry S, Ndour PA, Roussel C, et al. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 2014; 124:167.</a></li><li class=\"breakAll\">G&oacute;mez-Junyent J, Ruiz-Panales P, Calvo-Cano A, Gasc&oacute;n J, Mu&ntilde;oz J. Delayed haemolysis after artesunate therapy in a cohort of patients with severe imported malaria due to Plasmodium falciparum. Enferm Infecc Microbiol Clin. 2015:In Press.</li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/71\" class=\"nounderline abstract_t\">Hanson J, Anstey NM, Bihari D, et al. The fluid management of adults with severe malaria. Crit Care 2014; 18:642.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/72\" class=\"nounderline abstract_t\">Hanson JP, Lam SW, Mohanty S, et al. Fluid resuscitation of adults with severe falciparum malaria: effects on Acid-base status, renal function, and extravascular lung water. Crit Care Med 2013; 41:972.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi/abstract/73\" class=\"nounderline abstract_t\">Aung NM, Kaung M, Kyi TT, et al. The Safety of a Conservative Fluid Replacement Strategy in Adults Hospitalised with Malaria. PLoS One 2015; 10:e0143062.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 112633 Version 2.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1556270334\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1863622304\" id=\"outline-link-H1863622304\">INTRODUCTION</a></li><li><a href=\"#H463928145\" id=\"outline-link-H463928145\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3451033369\" id=\"outline-link-H3451033369\">Geographic distribution</a></li><li><a href=\"#H3881578288\" id=\"outline-link-H3881578288\">Transmission and risk factors for infection</a></li><li><a href=\"#H2574693641\" id=\"outline-link-H2574693641\">Life cycle</a></li></ul></li><li><a href=\"#H1765424253\" id=\"outline-link-H1765424253\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H2082101697\" id=\"outline-link-H2082101697\">Nonpregnant adults</a><ul><li><a href=\"#H3155318781\" id=\"outline-link-H3155318781\">- Uncomplicated infection</a></li><li><a href=\"#H2178070831\" id=\"outline-link-H2178070831\">- Severe infection</a></li><li><a href=\"#H3511702746\" id=\"outline-link-H3511702746\">- Laboratory findings</a></li></ul></li><li><a href=\"#H2936852948\" id=\"outline-link-H2936852948\">Children</a></li><li><a href=\"#H2234807279\" id=\"outline-link-H2234807279\">Pregnant women</a></li><li><a href=\"#H2673827734\" id=\"outline-link-H2673827734\">Asymptomatic infection</a></li></ul></li><li><a href=\"#H1623954686\" id=\"outline-link-H1623954686\">DIAGNOSIS</a></li><li><a href=\"#H3592481452\" id=\"outline-link-H3592481452\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H1359240066\" id=\"outline-link-H1359240066\">TREATMENT</a><ul><li><a href=\"#H1133672839\" id=\"outline-link-H1133672839\">Adults</a><ul><li><a href=\"#H4094566455\" id=\"outline-link-H4094566455\">- Uncomplicated infection</a></li><li><a href=\"#H889853449\" id=\"outline-link-H889853449\">- Severe infection</a><ul><li><a href=\"#H1117334877\" id=\"outline-link-H1117334877\">Antimalarial therapy</a></li><li><a href=\"#H3331312955\" id=\"outline-link-H3331312955\">Supportive care</a></li></ul></li></ul></li><li><a href=\"#H3071226439\" id=\"outline-link-H3071226439\">Children</a></li><li><a href=\"#H1354308628\" id=\"outline-link-H1354308628\">Pregnant women</a></li></ul></li><li><a href=\"#H2633272727\" id=\"outline-link-H2633272727\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H1556270334\" id=\"outline-link-H1556270334\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/112633|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/115652\" class=\"graphic graphic_figure\">- P. knowlesi map</a></li><li><a href=\"image.htm?imageKey=ID/115650\" class=\"graphic graphic_figure\">- P. knowlesi life cycle</a></li><li><a href=\"image.htm?imageKey=ID/80296\" class=\"graphic graphic_figure\">- Plasmodium blood smears</a></li></ul></li><li><div id=\"ID/112633|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/115654\" class=\"graphic graphic_table\">- Severe P. knowlesi malaria</a></li><li><a href=\"image.htm?imageKey=ID/53291\" class=\"graphic graphic_table\">- Features of malaria species</a></li><li><a href=\"image.htm?imageKey=ID/107830\" class=\"graphic graphic_table\">- ACTs for rx non-falciparum malaria</a></li><li><a href=\"image.htm?imageKey=ID/79194\" class=\"graphic graphic_table\">- Parenteral rx severe malaria</a></li><li><a href=\"image.htm?imageKey=ID/107719\" class=\"graphic graphic_table\">- Rx uncomplicated non-falciparum malaria pregnancy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">Antimalarial drugs: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">Clinical manifestations of malaria in nonpregnant adults and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">Diagnosis of malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diseases-potentially-acquired-by-travel-to-southeast-asia\" class=\"medical medical_review\">Diseases potentially acquired by travel to Southeast Asia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae\" class=\"medical medical_review\">Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-malaria-in-pregnant-women\" class=\"medical medical_review\">Prevention and treatment of malaria in pregnant women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-malaria\" class=\"medical medical_society_guidelines\">Society guideline links: Malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">Treatment of severe malaria</a></li></ul></div></div>","javascript":null}